APA (7th ed.) Citation

A, Y., M, C., AL, C., A, K., M, K., HC, L., . . . PK, C. (2026). Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. Journal of hepatology, 84(6), 1102. https://doi.org/10.1016/j.jhep.2026.01.006

Chicago Style (17th ed.) Citation

A, Yopp, et al. "Updated Data from IMbrave050: Adjuvant Atezolizumab Plus Bevacizumab for High-risk Hepatocellular Carcinoma." Journal of Hepatology 84, no. 6 (2026): 1102. https://doi.org/10.1016/j.jhep.2026.01.006.

MLA (9th ed.) Citation

A, Yopp, et al. "Updated Data from IMbrave050: Adjuvant Atezolizumab Plus Bevacizumab for High-risk Hepatocellular Carcinoma." Journal of Hepatology, vol. 84, no. 6, 2026, p. 1102, https://doi.org/10.1016/j.jhep.2026.01.006.